Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pediatric Drugs
Published in: Pediatric Drugs 6/2014

01-12-2014 | Review Article

Hidradenitis Suppurativa in Children and Adolescents: A Review of Treatment Options

Authors: Peter Riis Mikkelsen, Gregor B. E. Jemec

Published in: Pediatric Drugs | Issue 6/2014

Login to get access

Abstract

Hidradenitis suppurativa (HS) is a burdensome disease and has the potential to affect the life course of patients. It is a rare disease in children, and the recorded literature is correspondingly scarce. This article reviews the therapeutic options for HS in children and adolescents, and highlights particular differences or challenges with treating patients in this age group compared with adults. The work-up of paediatric patients with HS should include considerations of possible endocrine co-morbidities and obesity. Medical therapy of lesions may include topical clindamycin. Systemic therapy may include analgesics, clindamycin and rifampicin, finasteride, corticosteroids or tumour necrosis factor alpha (TNFα) blockers. Superinfections should be appropriately treated. Scarring lesions generally require surgery.
Literature
1.
2.
Kurzen H, Kurokawa I, Jemec GB, Emtestam L, Sellheyer K, Giamarellos-Bourboulis EJ, et al. What causes hidradenitis suppurativa? Exp Dermatol. 2008;17(5):455–6.PubMedCrossRef
3.
Fitzsimmons JS, Guilbert PR, Fitzsimmons EM. Evidence of genetic factors in hidradenitis suppurativa. Br J Dermatol. 1985;113(1):1–8.PubMedCrossRef
4.
Jemec GB. The symptomatology of hidradenitis suppurativa in women. Br J Dermatol. 1988;119(3):345–50.PubMedCrossRef
5.
Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35(2 Pt 1):191–4.PubMedCrossRef
6.
Jemec GB, Heidenheim M, Nielsen NH. A case–control study of hidradenitis suppurativa in an STD population. Acta Derm Venereol. 1996;76(6):482–3.PubMed
7.
Albares MP, Belinchon I, Ramos JM, Sanchez-Paya J, Betlloch I. Epidemiologic study of skin diseases among immigrants in Alicante, Spain. Actas Dermosifiliogr. 2012;103(3):214–22.PubMedCrossRef
8.
Cosmatos I, Matcho A, Weinstein R, Montgomery MO, Stang P. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;69(5):819.PubMedCrossRef
9.
Vazquez BG, Alikhan A, Weaver AL, Wetter DA, Davis MD. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013;133(1):97–103.PubMedCentralPubMedCrossRef
10.
Vinding GR, Miller IM, Zarchi K, Ibler KS, Ellervik C, Jemec GB. The prevalence of inverse recurrent suppuration: a population-based study of possible hidradenitis suppurativa. Br J Dermatol. 2014;170(4):884–9.PubMedCrossRef
11.
McMillan K. Hidradenitis suppurativa: number of diagnosed patients, demographic characteristics, and treatment patterns in the United States. Am J Epidemiol. 2014;179(12):1477–83.PubMedCrossRef
12.
13.
Trager JD, Kress DW, Kress DW. What’s your diagnosis? Painful nodules on the perineum with scarring and sinus tract formation. J Pediatr Adolesc Gynecol. 2006;19(1):45–8.PubMedCrossRef
14.
Feito-Rodriguez M, Sendagorta-Cudos E, Herranz-Pinto P, de Lucas-Laguna R. Prepubertal hidradenitis suppurativa successfully treated with botulinum toxin A. Dermatol Surg. 2009;35(8):1300–2.PubMedCrossRef
15.
Prabhu G, Laddha P, Manglani M, Phiske M. Hidradenitis suppurativa in a HIV-infected child. J Postgrad Med. 2012;58(3):207–9.PubMedCrossRef
16.
Randhawa HK, Hamilton J, Pope E. Finasteride for the treatment of hidradenitis suppurativa in children and adolescents. JAMA Dermatol. 2013;149(6):732–5.PubMedCrossRef
17.
Krakowski AC, Admani S, Uebelhoer NS, Eichenfield LF, Shumaker PR. Residual scarring from hidradenitis suppurativa: fractionated CO2 laser as a novel and noninvasive approach. Pediatrics. 2014;133(1):e248–51.PubMedCrossRef
18.
Rentea RM, Somers KK, Cassidy L, Enters J, Arca MJ. Negative pressure wound therapy in infants and children: a single-institution experience. J Surg Res. 2013;184(1):658–64.PubMedCrossRef
19.
von der Werth JM, Jemec GB. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol. 2001;144(4):809–13.PubMedCrossRef
20.
Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2007;56(4):621–3.PubMedCrossRef
21.
Matusiak L, Bieniek A, Szepietowski JC. Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol. 2010;90(3):264–8.PubMedCrossRef
22.
Onderdijk AJ, van der Zee HH, Esmann S, Lophaven S, Dufour DN, Jemec GB, et al. Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2013;27(4):473–8.PubMedCrossRef
23.
Smith HS, Chao JD, Teitelbaum J. Painful hidradenitis suppurativa. Clin J Pain. 2010;26(5):435–44.PubMedCrossRef
24.
Bilgic O, Bilgic A, Akis HK, Eskioglu F, Kilic EZ. Depression, anxiety and health-related quality of life in children and adolescents with vitiligo. Clin Exp Dermatol. 2011;36(4):360–5.PubMedCrossRef
25.
Schrader AM, Deckers IE, van der Zee HH, Boer J, Prens EP. Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol. 2014.
26.
Crowley JJ, Mekkes JR, Zouboulis CC, Scheinfeld N, Kimball A, Sundaram M, et al. Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities. Br J Dermatol. 2014.
27.
Kromann CB, Deckers IE, Esmann S, Boer J, Prens EP, Jemec GB. Risk-factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol. 2014.
28.
Dessinioti C, Katsambas A, Antoniou C. Hidradenitis suppurrativa (acne inversa) as a systemic disease. Clin Dermatol. 2014;32(3):397–408.PubMedCrossRef
29.
Thomas CL, Gordon KD, Mortimer PS. Rapid resolution of hidradenitis suppurativa after bariatric surgical intervention. Clin Exp Dermatol. 2014;39(3):315–7.PubMedCrossRef
30.
Kromann C, Ibler KS, Kristiansen V, Jemec GB. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol. 2014.
31.
Gold DA, Reeder VJ, Mahan MG, Hamzavi IH. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2014;70(4):699–703.PubMedCrossRef
32.
Scheinfeld N. Diseases associated with hidranitis suppurativa: part 2 of a series on hidradenitis. Dermatol Online J. 2013;19(6):18558.PubMed
33.
Canoui-Poitrine F, Le TA, Revuz JE, Viallette C, Gabison G, Poli F, et al. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. J Invest Dermatol. 2013;133(6):1506–11.PubMedCrossRef
34.
35.
Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case–control studies. J Am Acad Dermatol. 2008;59(4):596–601.PubMedCrossRef
36.
Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157(12):846–55.PubMedCrossRef
37.
Sartorius K, Emtestam L, Jemec GB, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009;161(4):831–9.PubMedCrossRef
38.
Miller I, Ellervik C, Vinding G, Zarchi K, Ibler KS, Knudsen KM, et al. Metabolic syndrome and inflammatory dermatological diseases—Hidradenitis Suppurativa. JAMA Dermatol. (In Press 2014).
39.
Scheinfeld N. Topical treatments of skin pain: a general review with a focus on hidradenitis suppurativa with topical agents. Dermatol Online J. 2014; 20(7).
40.
Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol. 1983;22(5):325–8.PubMedCrossRef
41.
Boer J, Jemec GB. Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa. Clin Exp Dermatol. 2010;35(1):36–40.PubMedCrossRef
42.
43.
Jahns AC, Killasli H, Nosek D, Lundskog B, Lenngren A, Muratova Z, et al. Microbiology of hidradenitis suppurativa (acne inversa): a histological study of 27 patients. APMIS. 2014.
44.
Sartorius K, Killasli H, Oprica C, Sullivan A, Lapins J. Bacteriology of hidradenitis suppurativa exacerbations and deep tissue cultures obtained during carbon dioxide laser treatment. Br J Dermatol. 2012;166(4):879–83.PubMedCrossRef
45.
Yazdanyar S, Jemec GB. Hidradenitis suppurativa: a review of cause and treatment. Curr Opin Infect Dis. 2011;24(2):118–23.PubMedCrossRef
46.
Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39(6):971–4.PubMedCrossRef
47.
Keller H. Comparison of the adverse effect profile of different substances such as penicillins, tetracyclines, sulfonamides and quinolones. Infection. 1991;19(Suppl 1):S19–24.PubMed
48.
Joks R, Durkin HG. Non-antibiotic properties of tetracyclines as anti-allergy and asthma drugs. Pharmacol Res. 2011;64(6):602–9.PubMedCrossRef
49.
Gu Y, Lee HM, Sorsa T, Simon SR, Golub LM. Doxycycline [corrected] inhibits mononuclear cell-mediated connective tissue breakdown. FEMS Immunol Med Microbiol. 2010;58(2):218–25.PubMedCrossRef
50.
51.
Bettoli V, Zauli S, Borghi A, Toni G, Minghetti S, Ricci M, et al. Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients. J Eur Acad Dermatol Venereol. 2014;28(1):125–6.PubMedCrossRef
52.
van der Zee HH, Boer J, Prens EP, Jemec GB. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology. 2009;219(2):143–7.PubMedCrossRef
53.
Gener G, Canoui-Poitrine F, Revuz JE, Faye O, Poli F, Gabison G, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology. 2009;219(2):148–54.PubMedCrossRef
54.
Mendonca CO, Griffiths CE. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol. 2006;154(5):977–8.PubMedCrossRef
55.
Tauber SC, Nau R. Immunomodulatory properties of antibiotics. Curr Mol Pharmacol. 2008;1(1):68–79.PubMedCrossRef
56.
Furustrand TU, Corvec S, Betrisey B, Zimmerli W, Trampuz A. Role of rifampin against Propionibacterium acnes biofilm in vitro and in an experimental foreign-body infection model. Antimicrob Agents Chemother. 2012;56(4):1885–91.CrossRef
57.
Smith K, Perez A, Ramage G, Gemmell CG, Lang S. Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin. Int J Antimicrob Agents. 2009;33(4):374–8.PubMedCrossRef
58.
Barth JH, Layton AM, Cunliffe WJ. Endocrine factors in pre- and postmenopausal women with hidradenitis suppurativa. Br J Dermatol. 1996;134(6):1057–9.PubMedCrossRef
59.
Lewis F, Messenger AG, Wales JK. Hidradenitis suppurativa as a presenting feature of premature adrenarche. Br J Dermatol. 1993;129(4):447–8.PubMedCrossRef
60.
Sawers RS, Randall VA, Ebling FJ. Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy. Br J Dermatol. 1986;115(3):269–74.PubMedCrossRef
61.
Mortimer PS, Dawber RP, Gales MA, Moore RA. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol. 1986;115(3):263–8.PubMedCrossRef
62.
Mortimer PS, Dawber RP, Gales MA, Moore RA. Mediation of hidradenitis suppurativa by androgens. Br Med J (Clin Res Ed). 1986;292(6515):245–8.CrossRef
63.
Harrison BJ, Kumar S, Read GF, Edwards CA, Scanlon MF, Hughes LE. Hidradenitis suppurativa: evidence for an endocrine abnormality. Br J Surg. 1985;72(12):1002–4.PubMedCrossRef
64.
65.
Jemec GB, Heidenheim M, Nielsen NH. Hidradenitis suppurativa—characteristics and consequences. Clin Exp Dermatol. 1996;21(6):419–23.PubMedCrossRef
66.
Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GB. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165(2):391–8.PubMedCrossRef
67.
Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62(2):205–17.PubMedCrossRef
68.
Lee RA, Dommasch E, Treat J, Sciacca-Kirby J, Chachkin S, Williams J, et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2009;60(4):565–73.PubMedCentralPubMedCrossRef
69.
Boer J, van Gemert MJ. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol. 1999;40(1):73–6.PubMedCrossRef
70.
Soria A, Canoui-Poitrine F, Wolkenstein P, Poli F, Gabison G, Pouget F, et al. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients’ outcome assessment. Dermatology. 2009;218(2):134–5.PubMedCrossRef
71.
Matusiak L, Bieniek A, Szepietowski JC. Acitretin treatment for hidradenitis suppurativa: a prospective series of 17 patients. Br J Dermatol. 2014;171(1):170–4.PubMedCrossRef
72.
Boer J, Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer? Br J Dermatol. 2011;164(1):170–5.PubMedCrossRef
73.
Brecher AR, Orlow SJ. Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol. 2003;49(2):171–82.PubMedCrossRef
74.
Stahle M, Atakan N, Boehncke WH, Chimenti S, Dauden E, Giannetti A, et al. Juvenile psoriasis and its clinical management: a European expert group consensus. J Dtsch Dermatol Ges. 2010;8(10):812–8.PubMed
75.
van der Zee HH, Prens EP, Boer J. Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol. 2010;63(3):475–80.PubMedCrossRef
76.
van Hattem S, Spoo JR, Horvath B, Jonkman MF, Leeman FW. Surgical treatment of sinuses by deroofing in hidradenitis suppurativa. Dermatol Surg. 2012;38(3):494–7.PubMedCrossRef
77.
78.
Dalrymple JC, Monaghan JM. Treatment of hidradenitis suppurativa with the carbon dioxide laser. Br J Surg. 1987;74(5):420.PubMedCrossRef
79.
Finley EM, Ratz JL. Treatment of hidradenitis suppurativa with carbon dioxide laser excision and second-intention healing. J Am Acad Dermatol. 1996;34(3):465–9.PubMedCrossRef
80.
Lapins J, Sartorius K, Emtestam L. Scanner-assisted carbon dioxide laser surgery: a retrospective follow-up study of patients with hidradenitis suppurativa. J Am Acad Dermatol. 2002;47(2):280–5.PubMedCrossRef
81.
Hazen PG, Hazen BP. Hidradenitis suppurativa: successful treatment using carbon dioxide laser excision and marsupialization. Dermatol Surg. 2010;36(2):208–13.PubMedCrossRef
82.
Kaplan I, Sarig A, Taube E, Ben-Bassat M. The CO2 laser in pediatric surgery. J Pediatr Surg. 1984;19(3):248–57.PubMedCrossRef
83.
Buimer MG, Ankersmit MF, Wobbes T, Klinkenbijl JH. Surgical treatment of hidradenitis suppurativa with gentamicin sulfate: a prospective randomized study. Dermatol Surg. 2008;34(2):224–7.PubMedCrossRef
84.
Yazdanyar S, Boer J, Ingvarsson G, Szepietowski JC, Jemec GB. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology. 2011;222(4):342–6.PubMedCrossRef
85.
Blok JL, van Hattem S, Jonkman MF, Horvath B. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol. 2013;168(2):243–52.PubMedCrossRef
86.
Verdolini R, Clayton N, Smith A, Alwash N, Mannello B. Metformin for the treatment of hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol. 2013;27(9):1101–8.PubMedCrossRef
87.
Dreno B, Khammari A, Brocard A, Moyse D, Blouin E, Guillet G, et al. Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol. 2012;148(2):182–6.PubMedCrossRef
88.
O’Reilly DJ, Pleat JM, Richards AM. Treatment of hidradenitis suppurativa with botulinum toxin A. Plast Reconstr Surg. 2005;116(5):1575–6.PubMedCrossRef
89.
Khoo AB, Burova EP. Hidradenitis suppurativa treated with Clostridium botulinum toxin A. Clin Exp Dermatol. 2014;39(6):749–50.PubMedCrossRef
90.
Xu LY, Wright DR, Mahmoud BH, Ozog DM, Mehregan DA, Hamzavi IH. Histopathologic study of hidradenitis suppurativa following long-pulsed 1064-nm Nd:YAG laser treatment. Arch Dermatol. 2011;147(1):21–8.PubMedCrossRef
91.
Tierney E, Mahmoud BH, Hexsel C, Ozog D, Hamzavi I. Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser. Dermatol Surg. 2009;35(8):1188–98.PubMedCrossRef
92.
Highton L, Chan WY, Khwaja N, Laitung JK. Treatment of hidradenitis suppurativa with intense pulsed light: a prospective study. Plast Reconstr Surg. 2011;128(2):459–65.PubMedCrossRef
Metadata
Title
Hidradenitis Suppurativa in Children and Adolescents: A Review of Treatment Options
Authors
Peter Riis Mikkelsen
Gregor B. E. Jemec
Publication date
01-12-2014
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 6/2014
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.1007/s40272-014-0091-3

Other articles of this Issue 6/2014

Pediatric Drugs 6/2014 Go to the issue

Acknowledgement to Referees

Acknowledgement to Referees

Therapy in Practice

Congenital Long QT Syndromes: Prevalence, Pathophysiology and Management

Therapy in Practice

Pharmacological Treatment of Chronic Non-Cancer Pain in Pediatric Patients

Therapy in Practice

Assessment and Management of Pain in Juvenile Idiopathic Arthritis

Systematic Review

The Role of Chemotherapy for Metastatic, Relapsed and Refractory Osteosarcoma

Review Article

Omalizumab in Children